Home › NDC Lookup › RxCUI directory › RxCUI 864661

Efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet — RxCUI 864661

RxNorm drug concept · Semantic clinical drug
RxCUI 864661 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI864661
Official nameEfavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asefavirenz 600 MG / 3TC 300 MG / Tenofovir disoproxil fumarate 300 MG Oral Tablet; efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)63 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Efavirenz, Lamivudine, and Tenofovir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Efavirenz — one of the three drugs in this tablet — commonly causes dizziness, unusual dreams, and trouble concentrating, especially in the first few weeks. Taking it at bedtime me...
  • Why do I have to take this on an empty stomach at bedtime?
  • This is really important: if you have hepatitis B, you should never stop this medication suddenly without talking to your doctor first. Two of the drugs in this tablet — lamivudine...
  • What should I do if I also have hepatitis B?
📖 Read our full Efavirenz, Lamivudine, and Tenofovir guide →

🕸️ Concept Web — How Efavirenz 600 MG / lamivudine 300 MG / tenofovir... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet RxCUI 864661

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Efavirenz 195085
    • Lamivudine 68244
    • Tenofovir disoproxil 300195
    • Efavirenz / lamivudine / tenofovir disoproxil 1008789
    • Tenofovir disoproxil fumarate 322248
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Symfi 2043459
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Efavirenz / lamivudine / tenofovir disoproxil Oral Tablet 864660
    • Efavirenz / lamivudine / tenofovir disoproxil fumarate Oral Tablet 2646004
    • Efavirenz / lamivudine / tenofovir disoproxil Oral Product 1161284
    • Efavirenz / lamivudine / tenofovir disoproxil Pill 1161285
    • Efavirenz / lamivudine / tenofovir disoproxil fumarate Oral Product 2659569
    • Efavirenz / lamivudine / tenofovir disoproxil fumarate Pill 2660547
    • Efavirenz / lamivudine / tenofovir disoproxil Oral Tablet [Symfi] 2043461
    • Efavirenz / lamivudine / tenofovir disoproxil fumarate Oral Tablet [Symfi] 2658846
    • +5 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Efavirenz 600 MG SCDC · 350652
  • Lamivudine 300 MG SCDC · 350655
  • Tenofovir disoproxil fumarate 300 MG SCDC · 393334
  • Efavirenz / lamivudine / tenofovir disoproxil Oral Tablet SCDF · 864660
  • Efavirenz / lamivudine / tenofovir disoproxil fumarate Oral Tablet SCDFP · 2646004
  • Efavirenz / lamivudine / tenofovir disoproxil Oral Product SCDG · 1161284
  • Efavirenz / lamivudine / tenofovir disoproxil Pill SCDG · 1161285
  • Efavirenz / lamivudine / tenofovir disoproxil fumarate Oral Product SCDGP · 2659569
  • Efavirenz / lamivudine / tenofovir disoproxil fumarate Pill SCDGP · 2660547

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 864661 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42385-0928-30 30 TABLET, FILM COATED in 1 BOTTLE (42385-928-30) Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Laurus Labs Limited 2020-05-14
42385-0928-90 90 TABLET, FILM COATED in 1 BOTTLE (42385-928-90) Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Laurus Labs Limited 2020-05-14
49502-0475-93 1 BOTTLE, PLASTIC in 1 CARTON (49502-475-93) / 30 TABLET, F... SYMFI Viatris Specialty LLC 2018-04-25
Observed labelers: Laurus Labs Limited (2) · Viatris Specialty LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.